

General Shareholders' Meeting 2025

Anne-Catherine Berner, new Grifols Chair

- *Grifols shareholders approve all proposed resolutions at the 2025 General Shareholders' Meeting*
- *The shareholders reelect Víctor Grifols Deu as a member of the Board of Directors, endorsing his in-depth knowledge of the business and his key role in the development and consolidation of the company's main strategic projects. They also ratified the appointment of Pascal Ravery as an independent director; Paul S. Herendeen has been designated as a company director*
- *In 2024, the company exceeded forecasts with revenues reaching €7,212 million and net profit of €157 million*
- *In addition, all planned innovation milestones were achieved in 2024, including the submission of fibrinogen approval applications in both the European Union and the United States*

Barcelona, Spain, June 5, 2025 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines and innovative diagnostic solutions, has appointed Anne-Catherine Berner as the new non-executive Chair of Grifols after its 2025 Annual Shareholders' Meeting. The newly appointed Chair succeeds outgoing Chairman, Thomas Glanzmann, who after two decades of dedication and commitment to the company did not stand for reelection.

Going forward, Grifols seeks to consolidate its strategy aimed at creating long-term sustainable value, with a firm commitment to research and innovation, as well as progress towards self-sufficiency in plasma.

Anne-Catherine Berner addressed Grifols shareholders: "It is an honor to be part of such an exceptional company, which for more than a century has improved the lives of millions of people. The values that have brought us this far are the cornerstones of our success and will continue to guide our path going forward. As Chair, I will work to maintain the high standards of quality, rigor, transparency and governance that characterize the company, and will look out for the best interests of our patients and donors with an eye on the long term."

Raimon Grifols, Grifols Vice-Chairman and Board member, took the opportunity to welcome the new Chair and thank the departing Chairman for his years of service: "Since joining the Board of Directors as an independent director in 2024, Anne has demonstrated her ability and vision to lead Grifols. We are convinced that her experience, judgment and leadership will make a decisive contribution to the company's success in this new phase. We also say a very special thank you to Thomas for 20 years of outstanding commitment to Grifols, always acting in the best interests of Grifols and its stakeholders."

Grifols' shareholders supported all the items on the agenda put to the vote at the 2025 General Shareholders' Meeting, held today at Grifols' headquarters in Sant Cugat del Vallès. 602 shareholders, holders of 297,122,195 Class A shares, representing 69.72% of the company's share capital with voting rights, were represented at the meeting. The broad support received at the

meeting reflects the confidence of the shareholders in Grifols' fundamental pillars and the company's strategic direction.

During the meeting, the shareholders supported the reelection of Víctor Grifols Deu as a member of the Board of Directors. His continuity on the company's governing body has been endorsed by his in-depth knowledge of the business and his key role in the development and consolidation of the company's main strategic projects in recent years, while guaranteeing the continuity of a vision aligned with Grifols' long-term objectives. In addition, the shareholders also approved the ratification of Pascal Ravery as an independent director. Paul S. Herendeen has been designated as a proprietary director by shareholders Flat Footed, Mason Capital and Sachem Head.

Other noteworthy proposals included the shareholders' endorsement of the 2024 financial statements, in which the company exceeded forecasts with revenues reaching €7,212 million, an increase of 10.3% at constant exchange rates, adjusted EBITDA of €1,779 million, with an operating margin of 24.7%, and net profit of €157 million. The company also reported that all the innovation milestones planned for 2024 have been reached, including the submission of fibrinogen approval applications both in the European Union and the United States.

Shareholders also endorsed the company's director compensation policy and stock incentive plan for 2025, as well as the reduction of the number of members of the Board of Directors to 12.

For more information: [Grifols General Shareholders' Meeting](#) and [Grifols Annual Integrated and Sustainability Report 2024](#).

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel.: +34 93 571 00 02

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.